1 completed, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow SY-5609: new trials by email Literature Review of SY-5609 trials Research Report on SY-5609
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) Inavolisib, Bevacizumab, Cetuximab - Metastatic Colorectal Cancer | Phase 1 | Recruiting | Hoffmann-La Roche | 542 | 2021-10-22 | 2026-11-06 |
| A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors SY-5609, Fulvestrant, Gemcitabine - Advanced Solid Tumor, Breast Cancer | Phase 1 | Completed | Syros Pharmaceuticals | 105 | 2020-01-23 | 2023-10-27 |
Breast Neoplasms (1) · Colorectal Neoplasms (1) · Pancreatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
Hoffmann-La Roche (1) · Syros Pharmaceuticals (1)
United States (2) · Australia (1) · Canada (1) · Denmark (1) · Germany (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
2023 (1)